e-learning
resources
Copenhagen 2005
Monday 19.09.2005
Information for the active clinician
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The debacillisation rate during controlled anti-TB therapy
S. Kos, J. Houskova, Z. Svecova (Mirosov, Pilsen, Czech Republic)
Source:
Annual Congress 2005 - Information for the active clinician
Session:
Information for the active clinician
Session type:
Oral Presentation
Number:
2802
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Kos, J. Houskova, Z. Svecova (Mirosov, Pilsen, Czech Republic). The debacillisation rate during controlled anti-TB therapy. Eur Respir J 2005; 26: Suppl. 49, 2802
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis.
Source: International Congress 2017 – MDRTB: detection and management
Year: 2017
Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation
Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB)
Year: 2006
Prevalence of inappropriate tuberculosis treatment regimens: a systematic review
Source: Eur Respir J 2012; 39: 1012-1020
Year: 2012
One year follow-up of T-SPOT. TB results in treated patients with active tuberculosis
Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease
Year: 2007
The main clinical problem of increasing resistance of
Mycobacterium tuberculosis
(MT) to first-line anti-TB drugs
Source: Eur Respir J 2005; 26: Suppl. 49, 654s
Year: 2005
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon?
Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Year: 2005
Patient choice promotes adherence in preventive treatment for latent tuberculosis
Source: Eur Respir J 2007; 30: 728-735
Year: 2007
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 340s
Year: 2001
The clinical and bacteriological basis for initiating a specific treatment
Source: Annual Congress 2006 - PG11 - Clinical highlights on tuberculosis
Year: 2006
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
The use of the lytic D29 mycobacteriophages for accelerated determination of the drug sensitivity of tuberculosis mycobacteria to first and second-line anti-TB drugs in clinical isolates obtained after initial cultivation
Source: Virtual Congress 2020 – Tuberculosis: part 2
Year: 2020
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001
The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007
Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs
Source: Eur Respir J 2002; 20: Suppl. 38, 614s
Year: 2002
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
IP-10 decreases during antituberculous treatment in children with active tuberculosis.
Source: Virtual Congress 2020 – Tuberculosis: part 2
Year: 2020
Diaskintest at patients after successful treatment of lung tuberculosis
Source: International Congress 2017 – Migrants and screening
Year: 2017
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept